With the government reportedly planning to flexibly apply the Incremental Cost-Effective Ratio (ICER) threshold, whether the breast cancer treatment Enhertu (fam-trastuzumab deruxtecan, Daiichi Sankyo) will finally find its way to reimbursement is gaining attention in Korea.

The drug’s reimbursement review is currently stuck in HIRA’s pharmacoeconomic evaluation stage. The drug was unable to pass the stage due to the longer period of administration, which rather increased drug cost, despite its significantly better effect than existing drugs.

Therefore, a more flexible application of the ICER threshold during pharmacoeconomic evaluation is expected to allow Enhertu’s passage. <